Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate

Journal of Internal Medicine

Volumn 255, Issue 1, 2004, Pages 125-129

  Ojetti, V ^a   Migneco, A ^a   Zocco, M A ^a   Nista, E C ^a   Gasbarrini, G ^a   Gasbarrini, A ^a,b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

lactamase inhibitor; Amoxicillin clavulanate; Higher H. pylori eradication rate; Omeprazole; Side effects; Triple therapy

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CLARITHROMYCIN; OMEPRAZOLE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; DYSPEPSIA; EPIGASTRIC PAIN; ERUCTATION; FEMALE; GASTROINTESTINAL DISEASE; HALITOSIS; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; UREA BREATH TEST;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; BETA-LACTAMASES; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; DYSPEPSIA; ENZYME INHIBITORS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PATIENT COMPLIANCE;

EID: 1642580749     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0954-6820.2003.01239.x     Document Type: Article

References (34)

1. Sanders MK, Peura DA. Helicobacter pylori-associated diseases. Curr Gastroenterol Rep 2002; 4: 448-54.
2. Tygat G. Helicobacter pylori: past, present and future. J Gastroenterol Hepatol 2000; 15 (Suppl. 3): G30-3.
3. Carloni E, Cremonini F, Di Caro S et al. Helicobacter pylori-related extradigestive diseases and effects of eradication therapy. Dig Liver Dis 2000; 32 (Suppl. 3): S214-6.
4. Gasbarrini A, Franceschi F, Armuzzi A et al. Extradigestive manifestations of Helicobacter pylori gastric infection. Gut 1999; 45 (Suppl. 1): 19-12.
5. Mitchell H, Megraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2002; 7 (Suppl. 1): 8-16.
6. Tursi A, Cammarota G, Papa A, Montalto M, Fedeli G, Gasbarrini G. Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication. Am J Gastroenterol 1996; 91: 1668-70.
7. Gasbarrini A, Ojetti V, Armuzzi A et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 79-83.
8. Horn J. The proton pump inhibitors: similarities and differences. Clin Ther 2000; 22: 266-80.
9. Bazzoli F. Italian omeprazole triple therapy: a 1 week regimen. Scand J Gastroenterol 1996; 215 (Suppl.): 118.
10. Bazzoli F, Pozzato P, Rokkas T. Helicobacter pylori: the challenge in therapy. Helicobacter 2002; 7 (Suppl. 1): 43-9.
11. Houben MH, Van Der Beek D, Hensen EF et al. A systematic review of Helicobacter pylori eradication therapy. The impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-55.
12. Huang JQ, Hunt RH. Treatment failure: the problem of non-responders. Gut 1999; 45 (Suppl. X): I40-4.
13. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001; 15: 1023-9.
14. Cremonini F, Di Caro S, Covino M et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744-9.
15. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998; 115: 1272-7.
16. Van Der Wouden EJ, Thijs JC, Van Zwet AA et al. Nitroimidazole resistance in Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 7-14.
17. Tankowic J, Lamarque D, Lascols C et al. The impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole- amoxicillin-clarithromycin therapy. Aliment Pharmacol Ther 2001; 15: 707-13.
18. Miller LA, Ratnam K, Payne DJ. Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr Opin Pharmacol 2001; 1: 451-8.
19. Horii T, Kimura T, Sato-Kawamura K, Nada T, Shibayama K, Ohta M. Beta-lactamase inhibitors have antibacterial activities against Helicobacter pylori. J Infect Chemother 1999; 5: 206-7.
20. Horii T, Mase K, Suzuki Y et al. Antibacterial activities of beta-lactamase inhibitors associated with morphological changes of cell wall in Helicobacter pylori. Helicobacter 2002; 7: 39-45.
21. Dore MP, Graham DY, Sepulveda AR, Realdi G, Osato MS. Sensitivity of amoxicillin-resistant Helicobacter pylori to other penicillins. Antimicrob Agents Chemother 1999; 43: 1803-4.
22. Vcev A, Vukovic D, Ivandic A et al. Another therapeutic schedule in eradication of Helicobacter pylori. Acta Med Croatica 1997; 51: 95-9.
23. Logan RP. Urea breath tests in the management of Helicobacter pylori infection. Gut 1998; 43 (Suppl. 1): S47-50.
24. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80 (Review).
25. deBoer WA, Thys JC, Borody TJ et al. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol 1996; 8: 641-3.
26. Buckley MJ, Scanlon C, McGurgan P, O'Morain CA. A validated dyspepsia symptom score. Ital J Gastroenterol Hepatol 1997; 29: 495-500.
27. The European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13.
28. Gasbarrini G, Malfertheiner P, Deltenre M et al. New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report. Ital J Gastroenterol Hepatol 1998; 30: S244-7.
29. Maconi G, Russo A, Imbesi V, Cucino C, Bianchi Porro G. Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile? Dig Liver Dis 2000; 32: 275-80.
30. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A. Rifabutin-based Helicobacter pylori eradication 'rescue' therapy. Aliment Pharmacol Ther 2001; 15: 143.
31. Cammarota G, Cianci R, Cannizzaro O et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1339-43.
32. Di Caro S, Ojetti V, Zocco MA et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 527-32.
33. Gerrits MM, Schuijffel D, van Zwet AA, Kuipers EJ, Vandenbroucke-Grauls CM, Kusters JG. Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori. Antimicrob Agents Chemother 2002; 46: 2229-33.
34. Sher LD, McAdoo MA, Bettis RB, Turner MA, Li NF, Pierce PF. A multicenter, randomized, investigator-blinded study of 5- and 10-day gatifloxacin versus 10-day amoxicillin/clavulanate in patients with acute bacterial sinusitis. Clin Ther 2002; 24: 269-81.